Immutep has received approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, to start the INSIGHT-005 Phase I trial of eftilagimod alpha (efti) along with BAVENCIO (avelumab) for the treatment of metastatic urothelial carcinoma, the most common bladder cancer type.
Jointly funded with Merck, the investigator-initiated, open-label study will evaluate the safety and efficacy of the dual immuno-oncology (IO) combination therapy in around 30 patients.
Go deeper with GlobalData
As a part of INSIGHT platform, the study will be conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt, Germany.
It consists of five different arms from stratums A to E and is designed for the investigation of efti in different combination treatments and routes of administration.
Immutep CEO Marc Voigt said: “In addition to possibly bringing a new chemo-free treatment option to patients with advanced urothelial cancer, we hope to further build upon the encouraging clinical data we have seen to date combining efti and avelumab in other challenging cancers.
“Efti’s unique activation of antigen-presenting cells to fight cancer has shown a benefit with avelumab, and we believe this dual IO-IO approach has broad potential to drive superior clinical outcomes across a variety of indications, including bladder cancer where avelumab monotherapy has regulatory approval.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEarlier, the dual therapy was assessed in the INSIGHT-004 Phase I trial for the treatment of patients with advanced solid tumours.
The study showed deep and durable responses in patients with low or negative PD-L1 expression as well as immuno-oncology insensitive tumours.
